Effects of combined use of Urinary Kallidinogenase on ET-1, NO, Hemorrheology and clinical efficacy in patients with moderate and severe cerebral watershed infarction

Wei DENG,Yan-li SUN,Guang-xian NAN
DOI: https://doi.org/10.13429/j.cnki.cjcr.2018.04.009
2018-01-01
Abstract:Objective To observe the clinical efficacy of urinary kallidinogenase combined with Butylphthalide in the treatment of moderate and severe acute cerebral watershed infarction (ACWI) and its influence on plasma endothelin-1 (ET-1), nitric oxide (NO) and hemorheology indicators. Methods A total of 108 patients with moderate and severe ACWI [National Institutes of Health Stroke Scale (NIHSS) more than 4] treated from February 2015 to November 2016 were selected and randomly divided into control group and treatment group (n = 54, each). On the basis of conventional antiplatelet aggregation and atherosclerosis, Butylphthalide injection was given in control group, and it combined with Urinary kallidinogenase was given in treatment group. The therapy was continued for 2 weeks in both groups. ET-1 and NO, hemorheology indexes (plasma viscosity, erythrocyte deposited, fibrinogen), and scores of NIHSS and ability of daily life (ADL) were observed before and after the treatment. Clinical efficacy and incidence of adverse reactions were compared between two groups. Results At 2 weeks after treatment, the total effective rate in treatment group was significantly higher than that in control group (92.59% vs 72.22%, P < 0.01). The levels of plasma ET-1, plasma viscosity, erythrocyte deposited, fibrinogen and NIHSS scores were significantly lower at 2 weeks after treatmet than those before treatment in both two groups (all P < 0.01), and were significantly lower in treatment group than those in control group (all P < 0.01). The level of plasma NO and ADL scores obviously increased in both two groups compared with pre-treatment and were statistically higher in treatment group than those in control group(all P < 0.01). The adverse reaction rate was 3.70% during treatment in both two groups. Conclusion Urinary kallidinogenase combined with Butylphthalide may be more effective in correcting plasma ET-1, NO, plasma viscosity, erythrocyte deposited and fibrinogen, improving vascular endothelial function and hemorheology, as well as promoting neurological function recovery in the treatment of ACWI.
What problem does this paper attempt to address?